Kaljusto Mari-Liis, Rutkovsky Arkady, Stensløkken Kåre-Olav, Vaage Jarle
Department of Cardiothoracic Surgery, Ullevål University Hospital, University of Oslo, Oslo, Norway.
Interact Cardiovasc Thorac Surg. 2010 May;10(5):743-8. doi: 10.1510/icvts.2009.217083. Epub 2010 Feb 5.
Ischemic postconditioning and inhibition of the reverse mode of the sodium-calcium exchanger (NCX) are both cardioprotective. We hypothesized that a combination of these techniques might have an additive effect mediated by protein kinases (see below). Isolated perfused mouse hearts were subjected to 35 min of ischemia and 60 min of reperfusion. Each series had its own control ischemia group, the other groups were postconditioning with three cycles of 10 s of reperfusion and 10 s of ischemia immediately after sustained ischemia; the vehicle of the NCX blocker KB-R7943 was added to the perfusate 5 min before ischemia in series 1; KB-R7943 was added to the perfusate 5 min before ischemia with and without postconditioning in series 2; KB-R7943 was added to the perfusate for 5 min from the start of reperfusion with and without postconditioning in series 3. Infarct size was measured and cardiac function was evaluated. Phosphorylation of AKT, ERK1/2, PKCdelta and PKCepsilon was measured by immunoblotting. Postconditioning alone reduced infarct size by 37% and activated AKT (P=0.02). Blockade of NCX reduced infarct size when applied before ischemia (29%) and at start of reperfusion (32%). Combining NCX blockade with postconditioning abolished cardioprotection despite phosphorylation of ERK1/2 (P=0.03) and PKCepsilon (P=0.01).
缺血后适应和抑制钠钙交换体(NCX)的逆向模式均具有心脏保护作用。我们推测,这些技术的联合应用可能通过蛋白激酶介导产生相加效应(见下文)。将离体灌注的小鼠心脏进行35分钟缺血和60分钟再灌注处理。每个系列都有其自身的对照缺血组,其他组在持续性缺血后立即进行三个周期的再灌注10秒和缺血10秒的后适应处理;在系列1中,在缺血前5分钟将NCX阻滞剂KB-R7943的溶剂加入灌注液中;在系列2中,在缺血前5分钟加入KB-R7943,同时进行和不进行后适应处理;在系列3中,在再灌注开始时加入KB-R7943 5分钟,同时进行和不进行后适应处理。测量梗死面积并评估心脏功能。通过免疫印迹法检测AKT、ERK1/2、PKCδ和PKCε的磷酸化水平。单独进行后适应可使梗死面积减少37%并激活AKT(P=0.02)。在缺血前应用(29%)和再灌注开始时应用(32%)NCX阻滞剂可减少梗死面积。尽管ERK1/2(P=0.03)和PKCε(P=0.01)发生了磷酸化,但将NCX阻滞剂与后适应联合应用却消除了心脏保护作用。